COST-OFFSETS ASSOCIATED WITH THE NEW TRIPLETS AVAILABLE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RESOURCE CONSUMPTION DERIVED FROM ITALIAN REAL PRACTICE
Author(s)
Ripellino C1, Peduto I2, Heiman F3, Fioravanti L4, Rea M4, Demma F4
1freelance, Desio (mi), Italy, 2IQVIA, Milan, Italy, 3IQVIA, MILANO, Italy, 4Takeda, Rome, Italy
OBJECTIVES: The treatment of relapsed/refractory multiple myeloma (> METHODS: A cost-offset model was developed adopting the social perspective. Costs incurring during first and subsequent years of treatment or during the median duration of treatment were calculated. The analysis focused on the triplets today available in Italy: ixazomib, lenalidomide, dexamethasone (IRd); carfilzomib, lenalidomide, dexamethasone (KRd); elotuzumab, lenalidomide, dexamethasone (ERd); daratumumab, lenalidomide, dexamethasone (DRd); daratumumab, bortezomib, dexamethasone (DVd); panobinostat, bortezomib, dexamethasone (PaVd); and the combination lenalidomide, dexamethasone (Rd). The treatment schedules were derived from the respective Summaries of Product Characteristics. The healthcare resource utilization was derived from the current Italian clinical practice by means of face-to face interviews with six Italian physicians. Unit costs were collected from the Italian national tariff list. The median duration of therapy was derived from the pivotal studies. The model was developed in Microsoft Excel® RESULTS: Focusing on the triplets, the total annual non-drug costs at year 1 varied from about €4,000 (IRd) to about €21,000 (KRd). Regarding direct costs, administration was found to be the key driver of the expenditure. IRd, as oral therapies, did not result in the accumulation of administration costs while infusion/injection annual costs varied from €1,000 (DRd) to €3,300 (KRd) for therapies being administered in outpatient setting. Also indirect costs were higher for non-oral regimens (the highest being DVd at about €17,000) when compared with oral regimens (approximately at €1,800). Similar trends were observed for subsequent years of treatment and with regard to the median duration of treatment CONCLUSIONS: Oral therapies, including new triplets, are associated with lower total non-drug costs. Further analyses considering also drug acquisition costs, are required to estimate the net cost-offset
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PCN200
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology